MIROCALS: Efficacy and safety of low-dose Interleukin-2
Read about research we fund - Testing whether Interleukin-2 could be a potential treatment for MND.
- Research
Home initiation and monitoring of non-invasive ventilation versus hospital-based care in people with MND
Read about research we fund - Investigating whether home-based treatment using non-invasive ventilation could be more widely used for people living with MND.
- Research
Tofersen given green light by the European Commission
Tofersen given green light by the European Commission for treating people with MND
- News
Investigating individualised effects of low-dose interleukin-2 throughout the MIROCALS Clinical Trial
Read about research we fund - Using RNA from the MIROCALS trial to understand the effect IL-2 antibody treatment has on the immune system.
- Research
Statement regarding letter to ILTOO Pharma
Since our update last week, and with the support of our legal advisors, we have written a formal letter to ILTOO Pharma, the pharmaceutical company engaged by…
Professionals
This section has information for health and social care professionals who provide care and support for people living with MND.
- Professionals
Management by specific professions
This section includes information about the management of MND for specific professions.
- Professionals
MND Association patron Kevin Sinfield announces challenge number five
MND Association patron Kevin Sinfield announces challenge number five
- Event
- Fundraising
- News
Jersey Branch
Find out more about the Jersey Branch of the Motor Neurone Disease Association.
MND Association update: MIROCALS trial
MND Association update: MIROCALS trial
- Research